Elizabeth A. Mily - Bristol Myers Squibb


Elizabeth A. Mily

Executive Vice President, Strategy & Business Development

Elizabeth Mily is executive vice president, Strategy & Business Development, at Bristol Myers Squibb. In this role, she oversees the company strategy and all business development activities, including strategic partnerships, mergers and acquisitions, as well as other strategic initiatives. Elizabeth is instrumental in our approach to source scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline. Elizabeth was appointed to the position in March 2020.

“This is an exciting time for BMS as we renew our portfolio and position the company for sustained growth and long-term value. Our strategic business development efforts complement our internal research and development efforts, helping BMS accelerate breakthrough science for patients with serious unmet medical needs.” 

Prior to joining Bristol Myers Squibb, Elizabeth was a senior member of the Global Healthcare Group at Barclays where she led its Lifesciences business, including the BioPharma, Life Science Tools and Diagnostics sectors. Prior to joining Barclays, Elizabeth served as head of Corporate Strategy and Development at Thermo Fisher Scientific. Previously, she was a managing director and senior coverage officer within the Healthcare Department of the Investment Banking Division at Goldman, Sachs & Co.

Elizabeth holds a master of science in foreign service from Georgetown University and a bachelor of arts in German literature and European history from The Ohio State University. She was also a Fulbright Scholar to the Universities of Cologne and Hamburg, Germany. Elizabeth also completed a Congress-Bundestag scholarship in Bonn, Germany.

Elizabeth is an active alumnus of The Ohio State University, sitting on the Dean’s Advisory Council of the Fisher College of Business. She also serves as a trustee of the Stephen Gaynor School.  

Updated: October 2022